TEAD1 and renal cell carcinoma: Targeting the Hippo pathway and YAP/TAZ has been an active interest in conventional RCC tumors given implications of hypoxia inducible factor pathway [28], and these data additionally suggest that particularly non-clear cell RCC like MTSCC may similarly be sensitive to oral Tead1 inhibitors [29], which in turn could be combined with PD-1/PD-L1 agents.